About MHP Partnership

AN ALLIANCE TO CREATE A WORLD LEADER IN HEALTHCARE AND CLINICAL RESEARCH

Revive Research Institute is partnering with Michigan Healthcare Professionals (MHP) to further the goal of improving patient centered healthcare. The partnership of the two highly qualified, organization that share similar vision and values will accelerate development of innovative treatment strategies and improve patient’s healthcare.

MHP is a physician led and administered organization, with goals very similar to that of Revive Research Inc. The physicians at MHP are committed to patient’s wellbeing and always go an extra mile for ensuring patient’s safety. MHP places immense emphasis on solid team-work, following patient care protocols, and devising a treatment plan that is affordable for all patients.

The partnership will effectively expand the horizon for both organizations and the patients, by offering broader services, deeper therapeutic expertise, and enhanced patient care. With MHP’s brilliant physicians, and Revive’s experienced clinical research staff, dawn of a new era in therapeutic medicine

Dr. Jeffrey Margolis, MD.
President of MHP
Hematology, Oncology, Internal Medicine

CURING DISEASES AND CHANGING LIVES TOGETHER

What is MHP?

The MHP Board of Directors is responsible for the quality of care policies, the compliance of its physicians to follow best practice guidelines, and the metrics to monitor the outcomes of patient care. Michigan Healthcare Professionals is putting into practice what leaders in healthcare, as well as third-party purchasers of healthcare services, have been calling for within the modern practice of medicine.

About Partnership

The partnership brings together two rapidly growing organization with a common culture, and values centered at enhancing patient care. The patient’s welfare is at the heart of all operations carried out at both MHP and Revive Research Inc. MHP strives to offer the best possible treatment, whereas Revive aims to find cures to improve lives and cure diseases.

Our Doctors

Dr. Adil Akhtar

Oncology | Principal Investigator

Sub-Investigators
Dr. George Howard

Dr. Savitha Balaraman

Oncology | Principal Investigator

Sub-Investigators
Dr. Richard Zekman
Dr. Samer Ballouz
Dr. Lynette Sutkowi

Dr. Barry Feldman

Internal Medicine | Principal Investigator

Sub-Investigators
Dr. Jeffrey Lipsky
Dr. Jeffrey Provizer

Dr. Adil Akhtar

44344 Dequindre Road, Suite 260
Sterling Heights, MI 48314

Advanced Pancreatic Cancer

A Phase I/II randomized, double-blind, placebo-controlled trial (1-BETTER) examining XB2001 (anti-IL-1⍺ True Human antibody) in combination with ONIVYDE + 5-FU/LV (+folinic acid) in advanced pancreatic cancer.

Refer Patients

Breast Cancer

The Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer (OVELIA) study is a phase 3 trial assessing the safety and tolerability of TOL2506, combined with endocrine therapy, in premenopausal patients with HR+, HER2- negative breast cancer.

Refer Patients

Diffuse Large B-Cell Lymphoma

MOR208C310 – Phase 3, multicenter, open-label, randomized trial comparing the efficacy and safety of Tafasitamab plus Lenalidomide in addition to R-CHOP vs. R-CHOP only in high-intermediate and high-risk patients with newly diagnosed Diffuse Large B-Cell Lymphoma

Refer Patients

Efficacy of Cryotherapy Device with Oral Mucositis

A Randomized, Prospective, Multi-center Trial to Assess the Efficacy of a Cryotherapy Device Versus Best Supportive Oral Care in Mitigating Symptoms of Oral Mucositis in Patients Receiving Chemotherapy for the Treatment of Cancer.

Refer Patients

EGFRI-induced Acneiform Lesions in Metastatic Colorectal Cancer

EGFRI-induced Acneiform Lesions in Metastatic Colorectal Cancer
L-02-01 – Phase 2, multi-center, randomized, double-blind, placebo-controlled study of the efficacy and safety of two strengths of LUT014 Gel topically applied qd for 4 weeks in mCRC patients with EGFRI induced Grade 2 acneiform lesions

Refer Patients

Follicular Lymphoma

Phase 1b/3 double-blind, randomized, active-controlled, 3-stage, biomarker adaptive study of tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractory follicular lymphoma

Refer Patients

Indolent Non-Hodgkin’s Lymphoma

Phase 3, Randomized, Open-Label, Controlled, Multicenter Study of Zandelisib (ME-401) in Combination with Rituximab Versus Standard Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgkin’s Lymphoma (iNHL) – The COASTAL Study

Refer Patients

Malignant Myeloid Hematologic Neoplasms

An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of LNK01002 in Patients with Malignant Myeloid Hematologic Neoplasms.

Refer Patients

Metastatic Castration-Sensitive Prostate Cancer

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Talazoparib With Enzalutamide in Participants With DDR-Deficient Metastatic Castration-Sensitive Prostate Cancer.

Refer Patients

Positive Oropharyngeal Cancer

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Cemiplimab Versus the Combination of Cemiplimab With ISA101b in the Treatment of Subjects With HPV16-Positive Oropharyngeal Cancer (OPC).

Refer Patients

Predicting Immunotherapy Efficacy

Predicting immunotherapy efficacy from analysis of pretreatment tumor biopsies. We hypothesize that the results from these experiments will show that the OncoPrism™ assay will be predictive of efficacy of immunotherapy. Pre-treatment samples will be utilized for these analyses.

Refer Patients

Prevention of Chemotherapy-induced Myelosuppression

A Phase 1b/2 Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, for the Prevention of Chemotherapy-induced Myelosuppression.

Refer Patients

Relapsed/Refractory Myelofibrosis

This is a Phase 2, multicenter, open-label study to determine the safety and tolerability of TL-895 in subjects with relapsed/refractory myelofibrosis, Janus kinase inhibitor intolerant myelofibrosis, and Janus kinase inhibitor treatment ineligible myelofibrosis.

Refer Patients

Uncontrolled Pain Relief in Patients With Advanced Cancer

Plenitude – 4-week randomized, double-blind, placebo-controlled, parallel group design trial to evaluate the safety and efficacy of inhaled PPP001 (9.5% THC/2.5% CBD) vs. placebo on uncontrolled cancer pain in patients with symptoms related to advanced incurable cancer.

Refer Patients

Uterine Serous Carcinoma

Phase 2 open-label, multicenter study to evaluate the clinical activity, safety, pharmacokinetics (PK), and related biomarkers of ZN-c3 300 mg once daily (QD), in adult women with recurrent or persistent uterine serous carcinoma (USC).

Refer Patients

Dr. Savitha Balaraman

32255 Northwestern Hwy., Suite 150
Farmington Hills, MI 48334

Advanced Pancreatic Cancer

A Phase I/II randomized, double-blind, placebo-controlled trial (1-BETTER) examining XB2001 (anti-IL-1 True Human antibody) in combination with ONIVYDE + 5-FU/LV (+folinic acid) in advanced pancreatic cancer

Refer Patients

Breast Cancer

OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA): A Phase 3 Study Evaluating Ovarian Suppression Following Subcutaneous Administration of TOL2506 in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone–Receptor—Positive (HR+), human epidermal growth factor receptor 2 (HER2)–Negative Breast Cancer

Refer Patients

Diffuse Large B-Cell Lymphoma

Phase 3, multicenter, open-label, randomized trial comparing the efficacy and safety of Tafasitamab plus Lenalidomide in addition to R-CHOP vs. R-CHOP only in high-intermediate and high-risk patients with newly diagnosed Diffuse Large B-Cell Lymphoma

Refer Patients

Efficacy of Cryotherapy Device in Oral Mucositis

A Randomized, Prospective, Multi-center Trial to Assess the Efficacy of a Cryotherapy Device Versus Best Supportive Oral Care in Mitigating Symptoms of Oral Mucositis in Patients Receiving Chemotherapy for the Treatment of Cancer.

Refer Patients

EGFRI-induced Acneiform Lesions in Metastatic Colorectal Cancer

Phase 2, multi-center, randomized, double-blind, placebo-controlled study of the efficacy and safety of two strengths of LUT014 Gel topically applied qd for 4 weeks in mCRC patients with EGFRI induced Grade 2 acneiform lesions

Refer Patients

Follicular Lymphoma

Phase 1b/3 double-blind, randomized, active-controlled, 3-stage, biomarker adaptive study of tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractory follicular lymphoma

Refer Patients

Indolent Non-Hodgkin’s Lymphoma

Phase 3, Randomized, Open-Label, Controlled, Multicenter Study of Zandelisib (ME-401) in Combination with Rituximab Versus Standard Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgkin’s Lymphoma (iNHL) – The COASTAL Study

Refer Patients

Malignant Myeloid Hematologic Neoplasms

An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of LNK01002 in Patients with Malignant Myeloid Hematologic Neoplasms.

Refer Patients

Metastatic Castration-Sensitive Prostate Cancer

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Talazoparib With Enzalutamide in Participants With DDR-Deficient Metastatic Castration-Sensitive Prostate Cancer.

Refer Patients

Positive Oropharyngeal Cancer (OPC)

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Cemiplimab Versus the Combination of Cemiplimab With ISA101b in the Treatment of Subjects With HPV16-Positive Oropharyngeal Cancer (OPC)

Refer Patients

Predicting Immunotherapy Efficacy

Predicting immunotherapy efficacy from analysis of pretreatment tumor biopsies. We hypothesize that the results from these experiments will show that the OncoPrism™ assay will be predictive of efficacy of immunotherapy. Pre-treatment samples will be utilized for these analyses.

Refer Patients

Prevention of Chemotherapy-induced Myelosuppression

A Phase 1b/2 Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, for the Prevention of Chemotherapy-induced Myelosuppression.

Refer Patients

Relapsed/Refractory Myelofibrosis

A Phase 2, Open-label, Multicenter Study of TL-895 in Subjects with Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis and Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis

Refer Patients

Uterine Serous Carcinoma

Phase 2 open-label, multicenter study to evaluate the clinical activity, safety, pharmacokinetics (PK), and related biomarkers of ZN-c3 300 mg once daily (QD), in adult women with recurrent or persistent uterine serous carcinoma (USC).

Refer Patients

Dr. Barry Feldman

32255 Northwestern Hwy., Suite 130
Farmington Hills, MI 48334

Mild to moderate COVID-19 (IV infusion)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Patients With Mild to Moderate COVID-19

Refer Patients

Sargramostim use in COVID-19 to recover Patient Health

A randomized Phase 2b trial evaluating clinical outcomes of inhaled sargramostim in high-risk patients with mild-moderate COVID-19

Refer Patients

Adaptive Platform Treatment Trial for Outpatients with COVID-19

A protocol to evaluate the safety and efficacy of investigational agents for the treatment of symptomatic non-hospitalized adults with COVID-19. ACTIV-2/A5401 is a phase II/III randomized, blinded, controlled adaptive platform trial to efficiently evaluate agents.

Refer Patients

Symptomatic patients infected with SARS-CoV-2 (oral capsule)

A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rayaldee (calcifediol) Extended-release Capsules to Treat Symptomatic Patients Infected with SARS-CoV-2 (REsCue)

Refer Patients

Mild to Moderate COVID-19 Treatment

Double-blinded, placebo control, randomized, phase-3 clinical trial to evaluate clinical efficacy of Favipiravir in patients with mild-to-moderate symptoms related to COVID-19 infection.

Refer Patients

General Patients with COVID-19

Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients with Mild-Moderate COVID-19

Refer Patients

Mild to moderate COVID-19 TREATMENT

Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Adalimumab or Placebo in Patients with Mild-Moderate COVID-19

Refer Patients

Mild to moderate COVID-19 treatment (IV Infusion)

A Randomized, Double-blind, Placebo-controlled, phase ⅔ study to evaluate the efficacy and safety of LY3819253 and LY3832479 in participants with mild to moderate covid-19 illness.

Refer Patients

Learn More

If you require any further information, feel free to contact us at 248-564-1485.